208 related articles for article (PubMed ID: 21713725)
1. [Risk adapted treatment of osteoporosis].
Schute L
Dtsch Med Wochenschr; 2011 Jul; 136(27):1440; author reply 1440. PubMed ID: 21713725
[No Abstract] [Full Text] [Related]
2. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
[TBL] [Abstract][Full Text] [Related]
3. [First choice drug for treatment of osteoporosis and the strategic points for choice of drugs].
Soen S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():325-8. PubMed ID: 18159713
[No Abstract] [Full Text] [Related]
4. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
Horning JA; Czajka J; Uhl RL
Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
[No Abstract] [Full Text] [Related]
5. [Risk adapted treatment of osteoporosis].
Pfeilschifter J
Dtsch Med Wochenschr; 2011 Mar; 136(11):525-32. PubMed ID: 21387211
[No Abstract] [Full Text] [Related]
6. Screening for osteoporosis.
Croswell J
Am Fam Physician; 2011 May; 83(10):1201-2. PubMed ID: 21568255
[No Abstract] [Full Text] [Related]
7. Screening for osteoporosis: recommendation statement.
U.S. Preventive Services Task Force
Am Fam Physician; 2011 May; 83(10):1197-200. PubMed ID: 21568254
[No Abstract] [Full Text] [Related]
8. [Diphosphonate treatment of osteoporosis and risk of atypical femoral fractures].
Schwarz P
Ugeskr Laeger; 2012 Jan; 174(1-2):30. PubMed ID: 22233716
[No Abstract] [Full Text] [Related]
9. [The necessity of cost-effectiveness analysis in osteoporosis].
Lamy O; Krieg MA
Rev Med Suisse; 2007 Jun; 3(115):1521-5. PubMed ID: 17682796
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?
Gajic-Veljanoski O; Bayoumi AM; Tomlinson G; Khan K; Cheung AM
Osteoporos Int; 2012 Nov; 23(11):2681-92. PubMed ID: 22398856
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
12. Pricey osteoporosis remedy doesn't beat older drugs.
Consum Rep; 2009 Aug; 74(8):19. PubMed ID: 19824126
[No Abstract] [Full Text] [Related]
13. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
Jansen JP; Bergman GJ; Huels J; Olson M
Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791
[TBL] [Abstract][Full Text] [Related]
14. [Drug treatment of osteoporosis].
Fassbender WJ; Willmann B
Dtsch Med Wochenschr; 2014 Mar; 139(10):497-500. PubMed ID: 24570199
[No Abstract] [Full Text] [Related]
15. PHARMAC responds on agents to prevent osteoporotic fractures.
Metcalfe S; Wilkinson T; Rasiah D
N Z Med J; 2006 Mar; 119(1230):U1895. PubMed ID: 16532056
[No Abstract] [Full Text] [Related]
16. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
[TBL] [Abstract][Full Text] [Related]
17. [A-TOP research group/JOINT-02].
Kuroda T; Ohta H; Shiraki M; Miyakawa N; Hosoi T; Nakamura T; Fukunaga M; Orimo H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():271-4. PubMed ID: 18161118
[No Abstract] [Full Text] [Related]
18. [Absolute risk for fracture and WHO guideline. Treatment of patients with secondary osteoporosis].
Yamauchi M;
Clin Calcium; 2007 Jul; 17(7):1106-13. PubMed ID: 17607079
[TBL] [Abstract][Full Text] [Related]
19. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
[TBL] [Abstract][Full Text] [Related]
20. Inappropriate prescribing for osteoporosis.
Seeman E; Kotowicz MA; Nash PT; Sambrook PN
Med J Aust; 2009 Sep; 191(6):355; author reply 355-6. PubMed ID: 19769562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
